Budipine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
| verifiedrevid = 437186133 | | verifiedrevid = 437186133 | ||
| IUPAC_name = 1-tert-butyl-4,4-diphenylpiperidine<ref>Martndale: The Complete Drug Reference, 35th Ed.</ref> | | IUPAC_name = 1-tert-butyl-4,4-diphenylpiperidine<ref>Martndale: The Complete Drug Reference, 35th Ed.</ref> | ||
| image = Budipine. | | image = Budipine.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| Line 46: | Line 46: | ||
| StdInChIKey = QIHLUZAFSSMXHQ-UHFFFAOYSA-N | | StdInChIKey = QIHLUZAFSSMXHQ-UHFFFAOYSA-N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
'''Budipine''' is an | ==Overview== | ||
'''Budipine''' is an antiparkinson agent. | |||
Its [[mechanism of action]] is not well characterized.<ref name="pmid16784759">{{cite journal |author=Reichmann H |title=Budipine in Parkinson's tremor |journal=J. Neurol. Sci. |volume=248 |issue=1-2 |pages=53–5 |date=October 2006 |pmid=16784759 |doi=10.1016/j.jns.2006.05.039 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-510X(06)00235-8}}</ref> It is believed to be an [[NMDA receptor antagonist]],<ref>J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048</ref> however, promoting the synthesis of [[dopamine]].<ref name="url">{{cite web |url=http://www.umm.edu/patiented/articles/what_other_drugs_used_parkinsons_disease_000051_8.htm |title=umm.edu |format= |work= |accessdate=}}</ref> | Its [[mechanism of action]] is not well characterized.<ref name="pmid16784759">{{cite journal |author=Reichmann H |title=Budipine in Parkinson's tremor |journal=J. Neurol. Sci. |volume=248 |issue=1-2 |pages=53–5 |date=October 2006 |pmid=16784759 |doi=10.1016/j.jns.2006.05.039 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-510X(06)00235-8}}</ref> It is believed to be an [[NMDA receptor antagonist]],<ref>J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048</ref> however, promoting the synthesis of [[dopamine]].<ref name="url">{{cite web |url=http://www.umm.edu/patiented/articles/what_other_drugs_used_parkinsons_disease_000051_8.htm |title=umm.edu |format= |work= |accessdate=}}</ref> | ||
| Line 59: | Line 64: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Antiparkinsonian agents]] | [[Category:Antiparkinsonian agents]] | ||
[[Category:Piperidines]] | [[Category:Piperidines]] | ||
[[Category:Drug]] | |||
Latest revision as of 13:43, 10 April 2015
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C21H27N |
| Molar mass | 293.446 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
|
WikiDoc Resources for Budipine |
|
Articles |
|---|
|
Most recent articles on Budipine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Budipine at Clinical Trials.gov Clinical Trials on Budipine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Budipine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating Budipine Risk calculators and risk factors for Budipine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Budipine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Budipine is an antiparkinson agent.
Its mechanism of action is not well characterized.[2] It is believed to be an NMDA receptor antagonist,[3] however, promoting the synthesis of dopamine.[4]
Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[5]
See also
References
- ↑ Martndale: The Complete Drug Reference, 35th Ed.
- ↑ Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
- ↑ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
- ↑ "umm.edu".
- ↑ Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.
Categories:
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Antiparkinsonian agents
- Piperidines
- Drug